The sulfacetamide sodium topical suspension, 10% (lotion) has been determined to be therapeutically equivalent to Sanofi-Aventis’s Klaron lotion, 10%, which is indicated for the topical treatment of acne.
Joseph Papa, chairman and CEO of Perrigo, said: “This approval is another example of our commitment to invest in and bring new products to market. It further demonstrates our strategy to deliver quality affordable healthcare both behind and over the counter.”